Dynavax Technologies Corporation - Common Stock (DVAX)

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

A fundamental and technical analysis of (NASDAQ:DVAX): Why DYNAVAX TECHNOLOGIES CORP (NASDAQ:DVAX) is Poised for High Growth.

DVAX earnings call for the period ending December 31, 2024.

What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025.

Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand.

DVAX earnings call for the period ending September 30, 2024.

DVAX earnings call for the period ending June 30, 2024.

DVAX stock results show that Dynavax Technologies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Latest regulatory update from Dynavax on HEPLISAV-B vaccine regimen for adults on hemodialysis, with FDA's Complete Response Letter.

DVAX earnings call for the period ending March 31, 2024.

DVAX stock results show that Dynavax Technologies missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

DVAX earnings call for the period ending December 31, 2023.